Trifluoroacetic acid → 1-(2-bromo-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)isoquinoline-6-sulfonamide
反応式
[Br:1][C:2]1[CH:7]=[C:6]([C:8]([F:11])([F:10])[F:9])[CH:5]=[CH:4][C:3]=1[C:12]1[C:21]2[C:16](=[CH:17][C:18]([S:22]([N:25](CC3C=CC(OC)=CC=3OC)[C:26]3[S:27][CH:28]=[CH:29][N:30]=3)(=[O:24])=[O:23])=[CH:19][CH:20]=2)[CH:15]=[CH:14][N:13]=1.C(O)(C(F)(F)F)=O>C(Cl)Cl>[Br:1][C:2]1[CH:7]=[C:6]([C:8]([F:9])([F:11])[F:10])[CH:5]=[CH:4][C:3]=1[C:12]1[C:21]2[C:16](=[CH:17][C:18]([S:22]([NH:25][C:26]3[S:27][CH:28]=[CH:29][N:30]=3)(=[O:24])=[O:23])=[CH:19][CH:20]=2)[CH:15]=[CH:14][N:13]=1参加物
実験手順
1-(2-bromo-4-(trifluoromethyl)phenyl)-N-(2,4-dimethoxybenzyl)-N-(thiazol-2-yl)isoquinoline-6-sulfonamide (see Example 70, step 3; 0.100 g, 0.150 mmol) was dissolved in DCM (1 mL). TFA (0.1 mL, 1.298 mmol) was added and the reaction was stirred for 30 minutes. The reaction was concentrated and the material was purified via silica gel column chromatography (12 g, gradient elution 0 to 10% MeOH:DCM) to afford 1-(2-bromo-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)isoquinoline-6-sulfonamide as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm=12.92 (br. s., 1H), 8.74 (d, J=5.8 Hz, 1H), 8.62 (d, J=1.4 Hz, 1H), 8.31-8.18 (m, 2H), 7.97 (d, J=7.9 Hz, 1H), 7.91 (dd, J=1.7, 8.9 Hz, 1H), 7.76 (d, J=7.9 Hz, 1H), 7.65 (d, J=8.8 Hz, 1H), 7.29 (d, J=4.3 Hz, 1H), 6.88 (d, J=4.5 Hz, 1H). m/z (ESI) 514.0 (M+H)+.
後処理
- concentrationThe reaction was concentrated
- customthe material was purified via silica gel column chromatography (12 g, gradient elution 0 to 10% MeOH:DCM)
出典と根拠
- ORDレコード
- ord-a91ebad8a64e41c8a401f45328e39675
- 出典データセット
- uspto-grants-2015_04
- 特許番号
- US09012443B2
反応ノート
読み込み中…